ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Johnson and Johnson

Johnson and Johnson (JNJ)

160.13
0.27
(0.17%)
Cerrado 01 Noviembre 2:00PM
160.13
0.00
( 0.00% )
Pre Mercado: 4:37AM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
160.13
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
297
0.00 Rango del Día 0.00
143.13 Rango de 52 semanas 168.85
Capitalización de Mercado [m]
Precio Anterior
160.13
Precio de Apertura
-
Última hora de negociación
04:34:16
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
6,033,714
Acciones en circulación
2,407,622,972
Rendimiento del Dividendo
3.10%
Ratio Precio/Utilidad
10.97
Beneficio por acción (BPA)
14.6
turnover
85.16B
Beneficio neto
35.15B

Acerca de Johnson and Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division ... Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
New Brunswick, New Jersey, USA
Fundado
-
Johnson and Johnson is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker JNJ. The last closing price for Johnson and Johnson was US$160.13. Over the last year, Johnson and Johnson shares have traded in a share price range of US$ 143.13 to US$ 168.85.

Johnson and Johnson currently has 2,407,622,972 shares in issue. The market capitalisation of Johnson and Johnson is US$385.53 billion. Johnson and Johnson has a price to earnings ratio (PE ratio) of 10.97.

Flujo de Opciones Johnson and Johnson (JNJ)

Flujo General

Pesimista

Prima Neta

-10k

Calls / Puts

433.33%

Comp. / Vent.

160.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

JNJ Últimas noticias

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease PR...

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis PR Newswire LAS VEGAS, Oct. 25, 2024 First-of-its-kind Phase 3b study...

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress PR Newswire TITUSVILLE, N.J., Oct. 24, 2024 New five-year data reinforce long-term safety and...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.91-0.565076999503161.04162.17159.03025944535160.37838786CS
4-0.12-0.0748829953198160.25166.75158.955951775162.16534685CS
12-1.05-0.651445588783161.18168.85156.446033714162.79836139CS
2610.466.98870849202149.67168.85143.716631782156.27864777CS
528.355.5013835815151.78168.85143.136970812155.70234008CS
156-4.805-2.91326886349164.935186.69143.138540003164.39441261CS
26028.3321.4946889226131.8186.69109.168093616159.71575049CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VATEINNOVATE Corp
US$ 6.60
(11.49%)
396
CLPRClipper Realty Inc
US$ 6.50
(10.17%)
1
STEMStem Inc
US$ 0.44
(10.14%)
5.57k
NRDYNerdy Inc
US$ 0.915
(9.06%)
12
ICLICL Group Ltd
US$ 4.42
(6.51%)
6.65k
OKLOOklo Inc
US$ 20.45
(-5.63%)
117.87k
SYYSysco Corp
US$ 71.00
(-5.37%)
248
PSQHPSQ Holdings Inc
US$ 2.65
(-5.36%)
800
SQNSSequans Communications SA
US$ 2.47
(-5.00%)
167
VSTVistra Corp
US$ 113.81
(-4.77%)
36.44k
NIONIO Inc
US$ 5.17
(1.37%)
455.07k
IONQIonQ Inc
US$ 15.14
(1.95%)
202.87k
PLTRPalantir Technologies Inc
US$ 41.40
(-1.24%)
187.45k
SMRNuScale Power Corporation
US$ 18.30
(-3.73%)
143.54k
XPEVXPeng Inc
US$ 12.18
(5.73%)
143.23k

JNJ Discussion

Ver más
IHuser IHuser 1 semana hace
imo... when my blonde haired comb over fat hero put the CEO of this pos out there to address the masses pushing vaccines.... I thought maybe he was playing th'old 4D Chess move.... they did not know I was playing 5D.


JNJ



IHuser
👍️0
EarningsCentral EarningsCentral 1 semana hace
👍️0
Monksdream Monksdream 3 semanas hace
JNJ 10Q due OCTOBER 15
👍️0
IHuser IHuser 2 meses hace
DNFWM........I am Christ and and I will cast you to hell if you fuck with me period~
👍️0
Monksdream Monksdream 4 meses hace
JNJ 10Q due JULY17
👍️0
avxl_going_long avxl_going_long 6 meses hace
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
👍️0
Monksdream Monksdream 7 meses hace
JNJ 10Q due 4/16
👍️0
BottomBounce BottomBounce 10 meses hace
$JNJ has Total Debt (mrq) $29.92B
👍️0
IHuser IHuser 1 año hace
imo..... i have toppled bf starting w the evil worthless king flying red bull ace....those paying attention have watched in dismay...next!


JNJ PFE

IHuser
👍️0
IHuser IHuser 1 año hace
imo... this ticker is a toxic POS...FOLOW MY GROUP at PFE....


IHuser
👍️0
IHuser IHuser 1 año hace
imo...my global following will crash this stock.....and me....JNJ
👍️0
IHuser IHuser 1 año hace
imo.... if you are bullish on this ticker i will ruin you and your whole life....f with me JNJ


IHuser
👍️0
DewDiligence DewDiligence 1 año hace
JNJ’s KVUE spin-off now has its own iHub board:

https://investorshub.advfn.com/Kenvue-Inc-KVUE-42070
👍️0
1jas 1jas 1 año hace
anyone here, read about enzolytics pharm announcing the now have a cure for hiv/aids called clone 3 yesterday.
👍️0
Enterprising Investor Enterprising Investor 1 año hace
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer (8/21/23)

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Under the terms of the exchange offer, 8.0324 shares of Kenvue common stock will be exchanged for each share of Johnson & Johnson common stock accepted in the exchange offer.

According to the exchange agent, Computershare Trust Company, N.A., 802,707,331 shares of Johnson & Johnson common stock were validly tendered and not validly withdrawn, including 250,407,279 shares that were tendered by notice of guaranteed delivery. Johnson & Johnson intends to accept 190,955,436 of the tendered shares in exchange for the 1,533,830,450 shares of Kenvue common stock owned by Johnson & Johnson. Because the exchange offer was oversubscribed, Johnson & Johnson is accepting only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Johnson & Johnson common stock, or an "odd-lot," who have validly tendered all of their shares, will not be subject to proration, in accordance with the terms of the exchange offer.

Based on the total number of shares of Johnson & Johnson common stock reported to be tendered prior to the expiration of the exchange offer, it is estimated that approximately 23.8% of the tendered shares of Johnson & Johnson common stock will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures, as well as the number of "odd-lot" shares that were validly tendered and are not subject to proration. Johnson & Johnson expects to announce the final proration factor on August 23, 2023, promptly following the expiration of the guaranteed delivery period. Shares of Johnson & Johnson common stock tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly after the final proration factor is announced. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the dealer managers for the exchange offer.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

https://www.businesswire.com/news/home/20230821033927/en/Johnson-Johnson-Announces-Preliminary-Results-of-Kenvue-Inc.-Exchange-Offer
👍️0
Enterprising Investor Enterprising Investor 1 año hace
The Final Exchange Ratio is 8.0324 shares of KVUE per JNJ share (unless extended).

https://www.sec.gov/Archives/edgar/data/200406/000162828023029851/vwapday19.htm
👍️0
IHuser IHuser 1 año hace
imo... this ticker is culpable as any poisoning people...JNJ










IHuser
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 1 año hace
Type in a symbol by mistake and came up with this stock
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 1 año hace
Type in a symbol by mistake and came up with this stock
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 1 año hace
Nice long run
👍️0
fung_derf fung_derf 1 año hace
And.....?
👍️0
DewDiligence DewDiligence 1 año hace
Bankruptcy judge tosses JNJ’s proposed talc settlement:

https://www.wsj.com/articles/johnson-johnsons-second-talc-bankruptcy-case-thrown-out-74a63a13 A New Jersey bankruptcy judge threw out the second chapter 11 case that Johnson & Johnson filed to resolve its mass talc liabilities, again shutting down the healthcare-product company’s plan to achieve an $8.9 billion settlement [see #msg-171617699].

Judge Michael Kaplan of the U.S. Bankruptcy Court in Trenton, N.J., said that J&J affiliate LTL Management LLC, created to carry the company’s talc-related liabilities into bankruptcy, wasn’t in sufficient financial distress to warrant granting it the legal protections of chapter 11.
👍️0
DewDiligence DewDiligence 1 año hace
JNJ launches tax-free exchange offer for KVUE:

https://www.businesswire.com/news/home/20230723805654/en
👍️0
BottomBounce BottomBounce 1 año hace
J&J Vaccine and Guillain-Barré Syndrome: Information on the FDA Warning
https://www.yalemedicine.org/news/covid-vaccine-guillain-barre-syndrome $JNJ
👍️0
BottomBounce BottomBounce 1 año hace
Johnson & Johnson $JNJ Total Debt (mrq) $52.91B
👍️0
Agoura Guy Agoura Guy 1 año hace
***US FDA Revokes Emergency Use Authorization of J&J COVID-19 Vaccine***

***serious risk of blood clots***

TOO MANY DEAD PEOPLE.... JNJ KILLED TO MANY PATIENTS WITH THIS EXPERIMENTAL VACCINE POISON THAT HAD NO LONG TERM SAFETY TESTING!!!!!!

JNJ IS LIABLE FOR KILLING ALL THOSE INNOCENT PEOPLE!!!!!!

THESE CRIMINALS WILL BE SUED INTO OBLIVION!!!!!!!

SHORT THIS RANCID STOCK!!!!!!!!!


👍️ 1
DewDiligence DewDiligence 1 año hace
BMY/JNJ—Milvexian—>FDA Fast Track designation for_all_phase-3_indications:

https://finance.yahoo.com/news/milvexian-granted-u-fda-fast-105900364.html

The three Milvexian indications BMY/JNJ are pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF—see #msg-171338375.

FDA Fast Track status doesn’t mean much, but it makes a Priority Review of the NDAs somewhat more likely (if one or more of these phase-3 trials pan out).

Please see #msg-169818942 for additional background info.

p.s. This PR was issued yesterday.
👍️0
DewDiligence DewDiligence 1 año hace
JNJ’s talc settlement encounters a hitch:

https://endpts.com/talc-claimants-look-to-sue-jj-over-alleged-fraud-in-bankruptcy-case/
👍️0
DewDiligence DewDiligence 2 años hace
KVUE +22% on_first_day_of_trading, valuing_the_company_at ~$50B.
👍️0
DewDiligence DewDiligence 2 años hace
JNJ consumer spinoff, Kenvue IPOs @$22.00—starts_trading_today_as KVUE:

https://finance.yahoo.com/news/kenvue-begin-trading-york-stock-132500217.html

At the IPO price, KVUE’s market cap is ~$41B. Following the IPO, JNJ still owns about 90% of KVUE and plans to distribute the remainder to JNJ shareholders at some point.

Caution: KVUE bears 100% of JNJ’s talc liability outside of the US and Canada.
👍️0
Agoura Guy Agoura Guy 2 años hace
Holding Big Pharma ACCOUNTABLE: J & J To Pay Victims $8.9 Billion For Cancer Causing Baby Powder!!!!!

WHAT KIND OF MONSTERS RUN J & J?????

SMEARING CANCER ON BABIES???????

SHORT THIS CRAP TO OBLIVION!!!!!!!

👍️ 1
DewDiligence DewDiligence 2 años hace
Addendum—JNJ’s ex-North America talc liabilities are being transferred to the Kenvue spinoff, according to Kenvue’s SEC filings.
👍️0
DewDiligence DewDiligence 2 años hace
JNJ asserts_it_has_settled_North_America talc claims_for_an NPV_of_$8.9B_spread_over_25_years:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000200406/000020040623000037/jnj-20230404.htm On April 4, 2023, the Company announced that its wholly owned subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will efficiently resolve all current and future claims arising from cosmetic talc litigation against the Company and its affiliates in North America. The Company has agreed to contribute up to the present value of $8.9 billion over 25 years (nominal value approximately $12 billion) to resolve the North America talc claims… JNJ’s press release (https://www.sec.gov/Archives/edgar/data/200406/000020040623000037/a44238-kexhibit991.htm ) says: LTL also has secured commitments from over 60,000 current claimants to support a global resolution on these terms. Notably, the PR doesn’t say how many other ex-North America claimants there are (or will be) and what is meant by the phrase, “these terms.”
👍️0
DewDiligence DewDiligence 2 años hace
JNJ has earmarked $61.5B for talc liability, according to court documents:

https://www.fiercepharma.com/pharma/after-johnson-johnson-loses-again-bankruptcy-case-its-game-talc-lawsuits
👍️0
IHuser IHuser 2 años hace
imo...Mr. Putin and the white hat US are dropping these criminals...thank-you..from USA___JNJ
👍️0
BottomBounce BottomBounce 2 años hace
Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits https://www.rttnews.com/3340418/court-rejects-j-j-bankruptcy-petition-to-end-talc-cancer-lawsuits.aspx $JNJ
👍️0
Sesh Sesh 2 años hace
Whoops better start digging in the cushions for some change J&J!
👍️0
BottomBounce BottomBounce 2 años hace
$JNJ Book Value only $28.51
👍️0
BottomBounce BottomBounce 2 años hace
$JNJ has $32.03B DEBT
👍️0
IHuser IHuser 2 años hace
imo...no posts....yal want me to post godsmack....ok.......ready____JNJ
👍️0
IHuser IHuser 2 años hace
imo...
👍️0
IHuser IHuser 2 años hace
imo...
👍️0
IHuser IHuser 2 años hace
imo....thank you Mr. Putin for replying to my communication...we American citizens see through these assholes bs....ty. This is our channel now where you can hear directly from the American market and the American people without interference.... subject to ihub rules....imo JNJ

Huser
👍️0
IHuser IHuser 2 años hace
imo....all world leaders be warned I now own ihub sentiment with the people and you will have a very hard time getting past me to make war......because that is not what humantity wants........so......try me. JNJ
👍️0
IHuser IHuser 2 años hace
imo...DY i se your sentiments in the green room......we are taking this over period no miscellaneous mass poisoning allowed....i hear you DY......JNJ.

Huser
👍️0
IHuser IHuser 2 años hace
imo...WW3 is called off.......subliminally.....the trumps cued me to this post....humanity does not naturally fight humanity......we don't......so quit....the bs....JNJ......everybody has money....and thats a good thing.....JNJ
👍️0
IHuser IHuser 2 años hace
imo...i can talk directly to putin on this channel....people don't have the problem...speculators are the problem......and blood doesnt spend very well....JNJ...hee sees this post and agrees with me....JNJ.
👍️0
IHuser IHuser 2 años hace
imo...my johnson is smaller than this company...JNJ
👍️0
DewDiligence DewDiligence 2 años hace
BMY/JNJ—Milvexian phase-2 data in treatment of acute ischemic stroke…

PR:
https://finance.yahoo.com/news/breaking-results-phase-2-axiomatic-073600645.html

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2022/Bristol-Myers-Squibb-ESC-IR-2022-Event-Presentation.pdf

Milvexian is an oral inhibitor of Factor XIa being co-developed by BMY and JNJ (#msg-140083631). For BMY specifically, Milvexian is the company’s hope for replacing Eliquis revenue when Eliquis goes off-patent in 2028.

In the trial reported today, Milvexian + Plavix/aspirin was compared to Plavix/aspirin alone at five different Milvexian doses. Despite the lackluster results, which include a flat dose response, BMY/JNJ have committed to a phase-3 program for Milvexian in three indications: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF. The phase-3 trials are slated to start by year-end 2022 (see slide #13). Curiously, the three phase-3 indications do not include either of the indications tested in phase-2, which are treatment of acute ischemic stroke (see above) and VTE prevention (#msg-166773814).

The main competition for Milvexian is Bayer’s Asundexian, another oral FXIa inhibitor that just started phase-3 trials in AF/stroke prevention and treatment of acute ischemic stroke (https://www.businesswire.com/news/home/20220828005030/en ).

BMY has pegged Milvexian is a $5B+ opportunity (not risk adjusted—see slide #20), but this seems optimistic in light of the dataset released today.
👍️0
Tamtam Tamtam 2 años hace
Johnson and Johnson (JNJ)
179.53 ? -1.56 (-0.86%)
Volume: 16,367,427
👍️0

Su Consulta Reciente

Delayed Upgrade Clock